Investor Backing & Capital Strength:
Capital raised is described as substantial, with a $372M Series D in June 2024 led by a16z and participation from Sanofi, explicitly earmarked to grow the pipeline and AI platform. References to $600M+ in total funding and ongoing hiring point to a reinforced capital base supporting expansion.
Strategic Partnerships:
Collaborations with Sanofi and OpenAI are presented as first-in-class efforts to apply AI across drug development, signaling external validation and increased resourcing. A 2025 Sanofi licensing deal worth up to €545M further indicates the capability to progress and transact assets with blue‑chip partners.
Product Line Growth:
Pipeline activity is shown to be broadening via in‑licensing (e.g., a CNS‑penetrant TYK2 inhibitor in Dec 2025) and movement into the clinic, including first‑in‑human dosing on June 9, 2026. Together, these moves suggest more programs are entering and advancing through clinical stages.
